AAOS: Robotic-Assisted Total Knee Arthroplasty Does Not Reduce Early Revision
By Lori Solomon HealthDay Reporter
TUESDAY, Feb. 20, 2024 -- Robotic assistance does not reduce the risk for two-year, all-cause revision or aseptic loosening in cementless total knee arthroplasty (TKA) when compared with conventional arthroplasty, according to a study presented at the 2024 Annual Meeting of the American Academy of Orthopaedic Surgeons, held from Feb. 12 to 16 in San Francisco.
Gregory J. Kirchner, M.D., from the Penn State Milton S. Hershey Medical Center, and colleagues used the American Joint Replacement Registry to identify 9,220 patients with osteoarthritis, aged 65 years and older, who underwent primary TKA from January 2017 through March 2020 with cementless femur and tibial components. Conventional TKA was compared to robotic-assisted TKA for two-year all-cause linked revision.
The researchers found that all-cause, two-year revision was similar between robotic and conventional TKA (1.16 versus 1.30 percent). Robotic assistance was significantly associated with a higher risk for infection and mechanical loosening as reasons for revision. However, when adjusting for age, sex, and the Charlson comorbidity index, there was no statistical difference for the association between robotic use and revision for infection or mechanical loosening.
"Some patients desire a robotic-assisted TKA because they've heard it is better, but we've shown that there isn't a true benefit in terms of the likelihood of needing another surgery in the early period," coauthor Lucas E. Nikkel, M.D., from Johns Hopkins University in Baltimore, said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted February 2024
Read this next
Patients Can Take GLP-1 RA Medications Before Surgery
WEDNESDAY, June 12, 2024 -- Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications do slow gastric emptying but not by enough to warrant discontinuing medications before...
ASCO: Neoadjuvant Ipilimumab + Nivolumab Ups Survival in Resectable Melanoma
WEDNESDAY, June 5, 2024 -- Neoadjuvant ipilimumab plus nivolumab followed by surgery results in longer event-free survival than surgery followed by adjuvant nivolumab among...
Odds of Death Lower With Surgery for Hip Fracture in Patients With Dementia
MONDAY, June 3, 2024 -- For community-dwelling patients with dementia and fracture of the femoral head and neck, the odds of death are lower for those treated surgically...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.